The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

$HNST
$LUNG
Catalog/Specialty Distribution
Consumer Discretionary
Medical/Dental Instruments
Health Care
Get the next $HNST alert in real time by email

LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023.

"We are pleased to welcome Michael, Alissa and Andrea to our board of directors. All three leaders are proven experts in the consumer goods space. Their retail and digital expertise will strengthen our board by adding significant capabilities that support the company's growth plans." said Carla Vernón, CEO of The Honest Company. "I look forward to partnering with our entire board as we continue to advance our Transformation Initiative and long-term strategy in 2024."

Barkley, a seasoned consumer products executive, most recently served as the CEO of KIND LLC. At KIND, Barkley led the business through a new era of growth and expansion. He also spearheaded transformational change and performance acceleration at Pinnacle Foods and Johnson & Johnson. Barkley is a visionary leader who builds organizational capabilities to enable high-performing teams and deliver enduring value creation.

Lynch is an experienced industry leader across consumer products, healthcare, and technology. At Google, she worked with Fortune 500 companies to drive digital transformation in healthcare using data, analytics, and AI. Previously, she was Vice President at Johnson & Johnson, where she held P&L and strategy roles leading billion-dollar global businesses in the MedTech and Consumer Health sectors, including Baby and Skin Care. She currently serves on the Board of Directors of Pulmonx (NASDAQ:LUNG).

Turner, a global leader in supply chain and logistics management has a successful background which includes transformational impact at Fortune 500 companies across consumer goods, biotech and pharmaceuticals. As Senior Vice President, Global Customer Service and Logistics at Mondelēz, she strategized and led logistics during the COVID-19 pandemic for the $25 billion supply chain across 80 countries. Turner was also responsible for driving teams to solve complex supply chain problems at General Mills and Merck, delivering improved productivity and accelerating growth.

"Honest continues to drive strong performance and demonstrate the power of our brand. As we continue on this journey to drive stakeholder value, we welcome Michael, Alissa and Andrea's expertise. They join Honest during an exciting and pivotal time for the brand and I am confident these additions further transform the board as the company evolves our growth strategy," said James D. White, Chair of the Board of The Honest Company. "Their diverse backgrounds and areas of expertise will help elevate us to new heights for consumers and push our thinking even further."

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" or "would" or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements concerning the Company's performance and brand and the Company's ability to deliver on its Transformation Initiative and drive stakeholder value. You should not rely on forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this press release primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition and operating results. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled "Risk Factors" in the Annual Report, on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 16, 2023, and Quarterly Report on Form 10-Q for the quarters ended March 31, 2023, June 30, 2023 and September 30, 2023, respectively, filed with the Securities and Exchange Commission on May 9, 2023, August 8, 2023 and November 8, 2023, respectively, and subsequent filings with the Securities and Exchange Commission. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this press release or the earnings call referencing this press release. The results, events and circumstances reflected in the forward-looking statements may not be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements.

About The Honest Company

The Honest Company (NASDAQ:HNST) is a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care. Honest products are available via Honest.com, third-party ecommerce customers and approximately 51,000 retail locations across the United States, Canada and Europe. Based in Los Angeles, CA, the Company's mission, to inspire everyone to love living consciously, is driven by its values of transparency, trust, sustainability and a deep sense of purpose around what matters most to its consumers: their health, their families and their homes. For more information about the Honest Standard and the Company, please visit www.honest.com.

Investor Contact:

Elizabeth Bouquard

ebouquard@thehonestcompany.com 

Media Contact:

Jennifer Kroog Rosenberg

jrosenberg@thehonestcompany.com 



Primary Logo

Get the next $HNST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HNST
$LUNG

CompanyDatePrice TargetRatingAnalyst
3/10/2025$17.00Buy
D. Boral Capital
1/10/2025$6.00 → $7.00Market Perform
Telsey Advisory Group
12/17/2024$7.00Buy → Hold
Loop Capital
12/11/2024$17.00 → $7.50Buy → Neutral
Citigroup
11/13/2024$4.00 → $6.00Market Perform
Telsey Advisory Group
11/13/2024$5.75 → $8.00Buy
Alliance Global Partners
9/10/2024$6.50Buy
B. Riley Securities
8/6/2024$6.00Outperform
Northland Capital
More analyst ratings

$HNST
$LUNG
Press Releases

Fastest customizable press release news feed in the world

See more
  • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

    REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

    $LUNG
    Medical/Dental Instruments
    Health Care
  • The Honest Company Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    LOS ANGELES, March 18, 2025 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today announced that it made an inducement grant to Mr. Etienne von Kunssberg in connection with his employment as The Honest Company's new SVP, Supply Chain, effective February 24, 2025. Such grant was made under The Honest Company, Inc. 2023 Inducement Plan, which was approved and adopted on March 14, 2023, by the Company's Compensation Committee of the Board of Directors. The Compensation Committee granted Mr. von Kunssberg an aggregate of 115,122 restricted stock units under the 2023 Inducement Plan. T

    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary
  • EDAP Appoints Glen French to Board of Directors

    PDF Version LYON, France, March 3, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors.          "We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world's premier robotic HIFU technology platform."        

    $EDAP
    $LUNG
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

$HNST
$LUNG
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$HNST
$LUNG
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$HNST
$LUNG
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$HNST
$LUNG
SEC Filings

See more

$HNST
$LUNG
Leadership Updates

Live Leadership Updates

See more
  • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    $LUNG
    Medical/Dental Instruments
    Health Care
  • The Honest Company Announces Appointment of Dorria L. Ball as Chief People Officer

    LOS ANGELES, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The Honest Company, a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced Dorria L. Ball as the Company's new Chief People Officer (CPO), effective immediately. Ball has served in this role on an interim basis since August of 2023. Reporting directly to Carla Vernón, CEO of The Honest Company, Ball will continue working alongside Honest's executive leadership team and Board of Directors as the leader of the People & Workplace function. "At Honest, we believe that values, business performance, DEI, and

    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

$HNST
$LUNG
Financials

Live finance-specific insights

See more
  • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

    REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

    $LUNG
    Medical/Dental Instruments
    Health Care
  • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

    REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

    $LUNG
    Medical/Dental Instruments
    Health Care
  • The Honest Company to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

    LOS ANGELES, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a personal care company dedicated to creating cleanly-formulated and sustainably-designed products, today announced that it will report fourth quarter and full year 2024 financial results after the market closes on Wednesday, February 26, 2024. The Company will host an investor conference call and webcast to review fourth quarter and full year 2024 financial results at 1:45pm PT/4:45pm ET on the same day. The live webcast can be accessed at https://investors.honest.com. For those interested in participating in the conference call by phone, please go to this link: https://register.vevent.com/register/BI3db3ccf

    $HNST
    Catalog/Specialty Distribution
    Consumer Discretionary

$HNST
$LUNG
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more